AMETEK, Inc. is kicking off the new month with a major update: The global manufacturer has acquired LKC Technologies, a portfolio company of DW Healthcare Partners (DWHP).
Refresh me on these players.
Headquartered in Berwyn, Pennsylvania, AMETEK provides industrial technology solutions via two operating groups—the Electronic Instruments Group (EIG) and Electromechanical Group (EMG)—for niche markets across the globe.
As for LKC Technologies, the Germantown, Maryland-based medical technology company specializes in developing and manufacturing visual electrophysiology products, with a particular focus in diagnostic technology.
- More specifically: Electroretinography (ERG) and visual evoked potential (VEP) devices.
To note: DWHP, its now-former parent company, is a healthcare industry-focused private equity firm.
Any devices we may have heard of?
Indeed: The RETeval—the FDA 510(k)-cleared, first-ever handheld ERG / VEP device.
What it does: Detects functional stress within the retina and optic nerve pathways to give clinicians objective information and enable earlier detection, prediction, follow-up, and monitoring of retina and optic nerve diseases, such as glaucoma, diabetic retinopathy (DR), and inherited retinal dystrophies (IRDs).
Compatible with Mac and Windows systems, this light and portable device:
- Utilizes LKC’s patented and noninvasive sensor strip skin electrodes to prevent corneal contact
- Includes real-time pupillography that adjusts for pupil size and requires no dilation
See how it works for DR (with a visual).
Now to this acquisition.
LKC is now considered a subsidiary of AMETEK, operating within the Ultra Precision Technologies Division (UPTD) of its Electronic Instruments Group (EIG).
To note: EIG designs and manufactures advanced instruments for the aerospace, medical, power, energy, research, and industrial markets.
See here (page 5) for a closer look at this group.
So why add LKC?
With over 90 acquisitions made since 2000, AMETEK’s purchase of LKC supports its strategic growth model—which also includes an emphasis on technology innovation and global / market expansion.
As such: Integrating LKC’s portfolio into AMETEK’S EIG offerings further grows its pre-existing foothold in the medical instrumentation business, with a specialization in ophthalmic diagnostics.
Reports of the deal referred to it as a “textbook example of AMETEK’s playbook.”
- "They identify a focused, technology-driven segment with strong growth tailwinds and use their financial strength to add a platform that can be scaled. Integrating LKC's specialized solutions could open new cross-selling opportunities within their medical customer base,” stated one market analyst.
Pre-existing, you say?
Indeed. AMETEK already owns Reichert Technologies (a business unit within the UPTD EIG), which designs and manufactures high-quality diagnostic devices and precision analytical instruments for ophthalmic and optometric care.
- In speaking on this acquisition, AMETEK Chairman and and CEO David A. Zapico referred to LKC as “an excellent strategic fit with our Ultra Precision Technologies Reichert business, providing attractive market expansion opportunities and creating a broader ophthalmic product portfolio.”
And what’s in it for LKC?
The company’s existing customer base and technology-market reach stand to reap the benefits of AMETEK’s global presence spanning 150 operating locations in 31 countries.
Lastly, were any monetary details disclosed?
Nope. The companies made no mention of any price tag associated with this purchase.
But just to keep in mind: AMETEK recently reported a record $2 billion in its Q4 2025 sales—a 13% increase over Q4 2025—and a record $1.37 billion for its EIG (also a 13% increase from the previous year) for the same time period.